BioWorld
-
Opportunity to control epidemic narrowing, as epidemiology gaps frustrate researchers
-
Bio-Thera launches $241M pre-revenue IPO on Shanghai’s STAR; shares up 83% on debut
-
Shock away? Adrenomed’s adrecizumab hits phase II endpoint in septic shock
-
Biomarin’s BLA for Valrox gene therapy for hemophilia A accepted by FDA
-
Today's news in brief
-
Rare disease specialist Canbridge closes $98 million series D, eyes IPO next
-
Digital strategies key for Indian pharma
-
Esperion wins FDA approval for new cholesterol-lowering drug
-
Bench Press for Feb. 21, 2020
BioWorld MedTech
-
BD, Babson partner to make small-volume blood Dx a reality in wake of Theranos debacle
-
CMS adds three years to joint replacement demo, but device makers at low risk
-
Advanced med-tech companies MIXing it up with Canada’s first industry-led incubator
-
Today's news in brief
-
Aurora Science raises investment finance for early stage projects
-
Med-tech gainers and losers for Feb. 18-21, 2020
-
BioWorld MedTech Patent Highlights: Week 7
-
BioWorld MedTech’s Neurology Extra for Feb. 21, 2020
-
Trisalus initiates study for delivery tech to help patients with pancreatic tumors
BioWorld Asia
-
Researchers trace COVID-19’s family tree to battle outbreak and ‘infodemic’
-
South Korea’s VCs invested a record high $930M in bio and medical ventures last year
-
Kaipharm secures $4.2M in series A funding for drug-induced transcriptome database
-
News in brief
-
Medicinal cannabis company Zelira raises nearly AU$5 million as it gears up for commercialization
-
COVID-19 could prove an expensive distraction for life sciences
-
Clover produces subunit vaccine candidate S-Trimer for coronavirus
-
Australia ramps up efforts to fight coronavirus with genetic sequence in hand
-
WHO drawing research roadmap to combat coronavirus, newly named COVID-19
